Clinical Trials

Are you a woman 18 years old or older who has been diagnosed with LAM? This study is examining whether long-term treatment with medicine called sirolimus can stop lung damage in women who have LAM. This study takes place at multiple locations in the United States.

Are you between 14 and 22 weeks pregnant, and think that you might have obstructive sleep apnea (OSA) ? This study is testing whether using CPAP to treat obstructive sleep apnea in pregnant women can help lower the risk of hypertensive disorders during pregnancy. To participate in this study, you must be at least 18 years old. This study takes place in multiple locations in the United States.

Do you have a child with Down syndrome and obstructive sleep apnea who is treated with positive airway pressure (PAP)? This study is testing a new intervention that was informed by the families to help children with Down syndrome and obstructive sleep apnea stick to their PAP treatment. The study will test the effectiveness of a new treatment plan that involves regular telephone and in-person check-ins with a PAP specialist. This study is for 6 -18 year old and is located in Cincinnati, Ohio; and Philadelphia, Pennsylvania.

The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.

The study is to investigate that the worsening orthostatic tachycardia and symptoms after glucose ingestion in POTS patients are due to a greater increase in splanchnic venous capacitance and excessive blood pooling during an orthostatic challenge.

Do you have a family history of high cholesterol? Researchers are studying whether a particular medication can lower cholesterol in people with a family history of high cholesterol. You may be able to participate if you are 18 to 69 years old, have not had a heart attack or stroke recently, and do not have uncontrolled high blood pressure. This study will take place in Nashville, Tennessee.

The Investigators propose a randomized trial of smart texts versus usual care for 6 months. The Investigators will randomize 100 PAH patients to the mHealth intervention or usual care. The Investigators will test the effect of a text-based mHealth intervention on HRQOL in PAH using the PAH-specific emPHasis-10 questionnaire. The Investigators will also test the effect of an mHealth intervention on exercise capacity, measured by a supervised home-based 6MWD test. Finally, the Investigators will examine the effect of the intervention on time to clinical worsening (composite of PAH therapy escalation, PAH hospitalization, and death) one year after randomization.

The purpose of this study is to compare reintubation rates and outcomes of patients treated with high-flow nasal canula oxygen therapy (HFNC) and patients treated with provider choice of standard care.

In this study investigators propose to address the following hypotheses: 1) Reduction in dietary sodium will decrease inflammation in patients with rheumatoid arthritis (RA). 2) Reduction in dietary sodium will decrease blood pressure in patients with RA. 3) Reduction in dietary sodium will decrease tissue sodium in patients with RA.

Ventilated pediatric patients are frequently over-sedated and the majority suffer from delirium, a form of acute brain dysfunction that is an independent predictor of increased risk of dying, length of stay, and costs. Universally prescribed sedative medications-the GABA-ergic benzodiazepines-worsen this brain organ dysfunction and independently prolong duration of ventilation and ICU stay, and the available alternative sedation regimen using dexmedetomidine, an alpha-2 agonist, has been shown to be superior to benzodiazepines in adults, and may mechanistically impact outcomes through positive effects on innate immunity, bacterial clearance, apoptosis, cognition and delirium. The mini-MENDS trial will compare dexmedetomidine and midazolam, and determine the best sedative medication to reduce delirium and improve duration of ventilation, and functional, psychiatric, and cognitive recovery in our most vulnerable patients-survivors of pediatric critical illness.